Risperidone(ris peer’ i dohn)
Risperdal, Risperdal Consta, Risperdal M-TAB
PREGNANCY CATEGORY C
Drug Classes
Antipsychotic
Benzisoxazole
Therapeutic Actions
Indications
Treatment of schizophrenia
Delaying relapse in long-term treatment of schizophrenia
Short-term treatment of acute manic or mixed episodes associated with bipolar 1 disorder; alone or in combination with lithium or valproate (oral only)
Long-acting injection used as monotherapy or as adjunct to lithium or valproate for maintenance treatment of bipolar 1 disorder (Risperdal Consta)
Treatment of irritability (aggression, self-injury, temper tantrums, quickly changing moods) associated with autistic disorders in children and adolescents (5–16 yr)
Unlabeled uses: Treatment of OCD refractory to SSRIs; treatment of tics in Tourette syndrome; stuttering
Contraindications and Cautions
Contraindicated with hypersensitivity to risperidone, lactation.
Use cautiously with CV disease, pregnancy, renal or hepatic impairment, hypotension.
Available Forms
Tablets—0.25, 0.5, 1, 2, 3, 4 mg; oral solution—1 mg/mL; orally disintegrating tablets—0.25, 0.5, 1, 2, 3, 4 mg; powder for injection—12.5, 25, 37.5, 50 mg
Dosages
Adults
Schizophrenia
Initial treatment: 1 mg PO bid or 2 mg PO once daily; then gradually increase with daily dosage increments of 1 mg bid on the second and third days to a target dose of 3 mg PO bid by the third day. Range, 4–8 mg/day or 25 mg IM every 2 wk; do not exceed 50 mg IM every 2 wk.
Reinitiation of treatment: Follow initial dosage guidelines, using extreme care due to increased risk of severe adverse effects with reexposure.
Switching from other antipsychotics: Minimize the overlap period and discontinue other antipsychotic before beginning risperidone therapy.
Delaying relapse time in long-term treatment: 2–8 mg/day PO.
Bipolar 1 disorder
Long-term maintenance: 25–50 mg IM every 2 wk.
Bipolar mania
2–3 mg/day PO as a once daily dose; range 1–6 mg/day.
Pediatric patients with irritability associated with autistic disorder (5–17 yr)
Initially, 0.25 mg/day PO for patients weighing less than 20 kg or 0.5 mg/day for patients 20 kg or more. After at least 4 days, may increase to 0.5 mg/day for patients less than 20 kg or 1 mg/day for patients 20 kg or more. Maintain dosage for at least 14 days; may then increase in increments of 0.25 mg/day (less than 20 kg) or 0.5 mg/day (20 kg or more) at 2-wk intervals. Dose may be divided; give at bedtime if somolence occurs.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
